A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

Exclusion Criteria

• •History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic syndrome, or diabetes resulting from pancreatic disorder or secondary diabetes
• •Current use of any blood glucose lowering agent other than metformin
• •History of renal disease or clinically significant abnormal kidney function tests at Screening or Day -2
• •Presence of active hepatic disease or clinically significant abnormal liver function tests at Screening or Day -2
• •History of myocardial infarction, severe/unstable angina, or coronary revascularization procedure within 6 months of Day -2
• •History of clinically significant cardiac arrhythmias within 1 year of Day -2
• •Congestive heart failure and/or New York Heart Association (NYHA) class III or IV symptoms of heart failure
• •Subjects with uncontrolled Stage 3 hypertension
• •History of 2 or more emergency room visits, doctor's visits, or hospitalizations due to hypoglycemia within 6 months of Day -2
• •History of alcohol or drug abuse within 12 months of Screening
• •History of bowel resection \> 20 cm, any malabsorptive disorder, severe gastroparesis, and GI procedure for the purpose of weight loss that would slow gastric emptying
• •History of HIV or hepatitis C
• •Major surgery within 3 months of Day -2 or any planned surgery during the study
• •History of any active infection within 2 weeks of Day -2
• •History of pancreatitis
• •History of any malignancy within the last 5 years which would affect the diagnosis or assessment of LX4211 or sitagliptin
• •History of any serious adverse reaction or hypersensitivity to LX4211 or sitagliptin
• •Presence of any clinically significant physical, laboratory, or ECG findings or any concurrent condition at Screening that may interfere with the study in the opinion of the investigator
• •Triglycerides \> 1000 mg/dL at Screening or Day -2
• •Donation or loss of \>400 mL of blood or blood product within 8 weeks prior to Day -2
• •Use of any tobacco product for the duration of study participation
• •Use of corticosteroids within 2 weeks of Day 1
• •Use of digoxin or warfarin within 2 weeks prior to Screening